Press Releases

Atlanta, GA, and Santa Clara, CA — July 5, 2016 — Arbor Pharmaceuticals, LLC (“Arbor”) and XenoPort, Inc. (“XenoPort”) (NASDAQ: XNPT) today announced the successful completion of Arbor’s tender offer to purchase all issued and outstanding shares of XenoPort’s common stock for $7.03 per share in cash. The tender offer expired as scheduled at 11:59…

Atlanta, GA, and Santa Clara, CA — June 16, 2016 — Arbor Pharmaceuticals, LLC (“Arbor”) and XenoPort, Inc. (“XenoPort”) (NASDAQ: XNPT) announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the previously announced tender offer by Arbor’s wholly owned subsidiary, AP Acquisition Sub, Inc. (“Acquisition…

Atlanta, GA — Arbor Pharmaceuticals announced today the launch of Cetylev (acetylcysteine) effervescent tablets for oral solution, a new acetaminophen overdose antidote with a lemon-mint taste and smell. Acetaminophen overdose is the most common form of poisoning reported to Poison Control Centers in the United States. According to the National Institute of Health, acetaminophen overdose sends…

Acquisition expands neurology product portfolio  Enhances sales infrastructure Atlanta, GA, and Santa Clara, CA — May 23, 2016 — Arbor Pharmaceuticals, LLC (Arbor) and XenoPort, Inc. (XenoPort) (NASDAQ: XNPT) announced today that they have signed a definitive agreement under which Arbor will acquire XenoPort for $7.03 per share in cash, or a total equity value of…

Atlanta, GA — Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Cetylev (acetylcysteine effervescent tablets for oral solution). Cetylev is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute…

KKR to Invest in Arbor Pharmaceuticals Significant Minority Stake To Help Drive Continued Growth Atlanta, GA and New York, NY Gndash; December 4, 2014 – Arbor Pharmaceuticals (“Arbor”), a specialty pharmaceutical company, today announced that KKR, a leading global investment firm, is acquiring a significant minority stake in the company. Financial terms of the transaction…

Atlanta, GA — Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Sotylize (sotalol hydrochloride) oral solution. Sotylize is the first and only sotalol oral solution indicated for the treatment of documented life-threatening ventricular arrhythmias and the maintenance of normal sinus rhythm in patients with…

Atlanta, GA – Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its second New Drug Application (NDA). The NDA was originally filed with the FDA on December 23, 2013 and officially accepted for filing on February 23, 2014. Arbor’s first NDA, Nymalize® (nimodipine) oral solution, was approved in…

Takeda and Arbor enter into a license, development and commercialization agreement for EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. Deerfield, Ill., Osaka, Japan, and Atlanta, September 12, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC (“Arbor”) announced today that Takeda…

Atlanta, GA — Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Nymalize™ (nimodipine) oral solution. Nymalize was previously granted Orphan designation which provides seven years of market exclusivity. Nymalize is the first and only nimodipine oral solution indicated for the improvement of neurological outcome…